Issues in Pharmacokinetics and Pharmacodynamics of Anti-Infective Agents: Kill Curves versus MIC

The success of antimicrobial therapy is determined by complex interactions between an administered drug, a host, and an infecting agent. In a clinical situation, the complexity of these interactions is usually reflected by a high variability in the dose-response relationship. Therefore, to minimize the dose-response variability, key characteristics of the drug, the infecting agent and the host have to be taken into account for selecting an appropriate antibiotic and an appropriate dose. Failure to do so may result in either therapeutic failure or emergence of resistant strains. To date, dose and drug selection is mostly based on a static in vitro parameter, the MIC and on the drug′s serum concentration as a pharmacokinetic parameter. In practice, however, a pharmacodynamic effect in vivo is rather the result of a dynamic exposure of the infective agent to the unbound antibiotic drug fraction at the relevant effect site. Thus, static conditions in an in vitro setting hardly reflect a dynamic situation in a target organ under in vivo conditions. Furthermore, serum concentrations do not reflect the unbound concentrations at the target site. In recent years substantial efforts were devoted to systematically elucidate the dynamic relationship between pharmacokinetic and pharmacodynamic variables. The main concept of this pharmacokinetic-pharmacodynamic approach is to use the concentration-effect relationship of the drug of interest in dosage adjustment and product development in a logical way and minimize trial-and-error approaches (29, 80). This approach can potentially result in substantial savings of time and expenses and may help to avoid unnecessary and, hence, unethical clinical studies (97). Thus, dosages and dosing intervals of antimicrobial agents should be designed with reference to dynamic pharmacokinetic and pharmacodynamic parameters. Accordingly, several efficacy indices or surrogate markers that take into account both pharmacokinetic and pharmacodynamic information have been defined and used by different authors to describe the antibacterial activity of various classes of antimicrobial agents (100, 106, 59). Currently there are two main trends for antibiotic pharmacokinetic-pharmacodynamic models; those based on the MIC and those based on a kill-curve approach, both of which will be described in detail in the following.

[1]  A. Hoffman,et al.  Pharmacodynamic aspects of modes of drug administration for optimization of drug therapy. , 1999, Critical reviews in therapeutic drug carrier systems.

[2]  J. Rotschafer,et al.  An in Vitro Pharmacodynamic Model to Simulate Antibiotic Behavior of Acute Otitis Media with Effusion , 1992, Pharmaceutical Research.

[3]  O. Cars,et al.  In Vitro Studies of Pharmacodynamic Properties of Vancomycin against Staphylococcus aureus andStaphylococcus epidermidis , 1998, Antimicrobial Agents and Chemotherapy.

[4]  G. Drusano Human pharmacodynamics of beta-lactams, aminoglycosides and their combination. , 1990, Scandinavian journal of infectious diseases. Supplementum.

[5]  D. Reeves Advantages and disadvantages of an in-vitro model with two compartments connected by a dialyser: results of experiments with ciprofloxacin. , 1985, The Journal of antimicrobial chemotherapy.

[6]  J. Turnidge The Pharmacodynamics of β-Lactams , 1998 .

[7]  H. Derendorf Pharmacokinetic evaluation of beta-lactam antibiotics. , 1989, The Journal of antimicrobial chemotherapy.

[8]  J. Blaser,et al.  Once-daily dosing of aminoglycosides , 1995, European Journal of Clinical Microbiology and Infectious Diseases.

[9]  C. Wa Choosing an antibiotic on the basis of pharmacodynamics. , 1998 .

[10]  E. R. Garrett,et al.  KINETICS AND MECHANISMS OF ACTION OF ANTIBIOTICS ON MICROORGANISMS. I. REPRODUCIBILITY OF ESCHERICHIA COLI GROWTH CURVES AND DEPENDENCE UPON TETRACYCLINE CONCENTRATION. , 1964, Journal of pharmaceutical sciences.

[11]  Garrett Er Kinetics of antimicrobial action. , 1978, Scandinavian journal of infectious diseases. Supplementum.

[12]  J. Blaser,et al.  Use of an in-vitro kinetic model to study antibiotic combinations. , 1985, The Journal of antimicrobial chemotherapy.

[13]  M. Sachdeva,et al.  Binding affinity for penicillin-binding protein 2a correlates with in vivo activity of beta-lactam antibiotics against methicillin-resistant Staphylococcus aureus. , 1990, Journal of Infectious Diseases.

[14]  D. Nicolau,et al.  Optimal times above MICs of ceftibuten and cefaclor in experimental intra-abdominal infections , 1994, Antimicrobial Agents and Chemotherapy.

[15]  H. Derendorf Pharmacokinetic evaluation of -lactam antibiotics , 1989 .

[16]  Jerome J. Schentag,et al.  Achieving an Optimal Outcome in the Treatment of Infections , 1999, Clinical pharmacokinetics.

[17]  J. Turnidge,et al.  Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model. , 1988, The Journal of infectious diseases.

[18]  R. Hancock,et al.  Novel method for measurement of outer membrane permeability to new beta-lactams in intact Enterobacter cloacae cells , 1991, Antimicrobial Agents and Chemotherapy.

[19]  A. Smith,et al.  Correction for bacterial loss in in vitro dilution models , 1987, Antimicrobial Agents and Chemotherapy.

[20]  H. Chambers,et al.  Effects of dosage, peak and trough concentrations in serum, protein binding, and bactericidal rate on efficacy of teicoplanin in a rabbit model of endocarditis , 1990, Antimicrobial Agents and Chemotherapy.

[21]  Jerome J. Schentag,et al.  Potential Role of Pharmacokinetics, Pharmacodynamics, and Computerized Databases in Controlling Bacterial Resistance , 2000, Infection Control & Hospital Epidemiology.

[22]  E. R. Garrett,et al.  Kinetics and mechanisms of action of antibiotics on microorganisms. V. Chloramphenicol and tetracycline affected Escherichia coli generation rates. , 1966, Journal of pharmaceutical sciences.

[23]  Jerome J. Schentag,et al.  Integration of pharmacokinetics and pharmacodynamics of methicillin in curative treatment of experimental endocarditis. , 1984, The Journal of antimicrobial chemotherapy.

[24]  A. Medeiros,et al.  Net Effect of Inoculum Size on Antimicrobial Action of Ampicillin-Sulbactam: Studies Using an In Vitro Dynamic Model , 2006, Antimicrobial Agents and Chemotherapy.

[25]  M. Laurentie,et al.  Pharmacokinetic-pharmacodynamic model for spiramycin in staphylococcal mastitis. , 1996, Journal of veterinary pharmacology and therapeutics.

[26]  H. Derendorf,et al.  Pharmacokinetic-pharmacodynamic modelling of the in vitro antiinfective effect of piperacillin-tazobactam combinations. , 1997, International journal of clinical pharmacology and therapeutics.

[27]  I. Odenholt-Tornqvist Pharmacodynamics of beta-lactam antibiotics. Studies on the paradoxical and postantibiotic effects in vitro and in an animal model. , 1988, Scandinavian journal of infectious diseases. Supplementum.

[28]  Jianguo Zhi,et al.  Microbial pharmacodynamics of piperacillin in neutropenic mice of systematic infection due toPseudomonas aeruginosa , 1988, Journal of Pharmacokinetics and Biopharmaceutics.

[29]  T. Eden Long-standing otitis media with effusion--a convenient model for the study of antibiotic penetration to respiratory tract secretions. , 1985, Scandinavian Journal of Infectious Diseases. Supplementum.

[30]  Hartmut Derendorf,et al.  Modeling of Pharmacokinetic/Pharmacodynamic (PK/PD) Relationships: Concepts and Perspectives , 1999, Pharmaceutical Research.

[31]  K. Fuursted,et al.  Pharmacodynamics of Glycopeptides in the Mouse Peritonitis Model of Streptococcus pneumoniae orStaphylococcus aureus Infection , 2000, Antimicrobial Agents and Chemotherapy.

[32]  Jerome J. Schentag,et al.  Pharmacodynamic Modeling of Risk Factors for Ciprofloxacin Resistance in Pseudomonas aeruginosa , 2000, Infection Control & Hospital Epidemiology.

[33]  J. Guggenbichler,et al.  Kill kinetics of bacteria under fluctuating concentrations of various antibiotics. II. Description of experiments. , 1986, Chemotherapy.

[34]  J. Mordenti,et al.  Combination antibiotic therapy: comparison of constant infusion and intermittent bolus dosing in an experimental animal model. , 1985, Journal of Antimicrobial Chemotherapy.

[35]  Mary Jane Ferraro,et al.  Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically : approved standard , 2000 .

[36]  Claude Carbón,et al.  Piperacillin, tazobactam, and gentamicin alone or combined in an endocarditis model of infection by a TEM-3-producing strain of Klebsiella pneumoniae or its susceptible variant , 1992, Antimicrobial Agents and Chemotherapy.

[37]  E. R. Garrett,et al.  Kinetics and mechanisms of drug action on microorganisms. XIV. The action of fluorouracil, other uracils and derived nucleosides on the microbial kinetics of Escherichia coli. , 1972, Chemotherapy.

[38]  E. R. Garrett,et al.  Kinetics and Mechanisms of Drug Action on Microorganisms , 1969 .

[39]  T. D. Costa,et al.  AUIC — A General Target for the Optimization of Dosing Regimens of Antibiotics? , 1996, The Annals of pharmacotherapy.

[40]  L. Engstrand,et al.  New pharmacokinetic in vitro model for studies of antibiotic activity against intracellular microorganisms , 1996, Antimicrobial agents and chemotherapy.

[41]  Jerome J. Schentag,et al.  Comparison of the abilities of grepafloxacin and clarithromycin to eradicate potential bacterial pathogens from the sputa of patients with chronic bronchitis: influence of pharmacokinetic and pharmacodynamic variables. , 2000, The Journal of antimicrobial chemotherapy.

[42]  L. Peterson,et al.  Influence of protein binding on therapeutic efficacy of cefoperazone , 1989, Antimicrobial Agents and Chemotherapy.

[43]  S. Keil,et al.  Mathematical corrections for bacterial loss in pharmacodynamic in vitro dilution models , 1995, Antimicrobial agents and chemotherapy.

[44]  Jerome J. Schentag,et al.  Pharmacodynamic interactions of antibiotics alone and in combination. , 1998, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[45]  Jerome J. Schentag,et al.  The Importance of Pharmacokinetic/Pharmacodynamic Surrogate Markers to Outcome , 1995, Clinical pharmacokinetics.

[46]  W. Craig,et al.  Pharmacodynamics of fluoroquinolones in experimental models of endocarditis. , 1998, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[47]  Jerome J. Schentag Antimicrobial action and pharmacokinetics/pharmacodynamics: the use of AUIC to improve efficacy and avoid resistance. , 1999, Journal of chemotherapy.

[48]  J. Aeschlimann,et al.  Pharmacodynamic Analysis of the Activity of Quinupristin-Dalfopristin against Vancomycin-ResistantEnterococcus faecium with Differing MBCs via Time-Kill-Curve and Postantibiotic Effect Methods , 1998, Antimicrobial Agents and Chemotherapy.

[49]  H. Derendorf,et al.  Pharmacokinetic-Pharmacodynamic Modeling of the Antibiotic Effect of Piperacillin in Vitro , 2004, Pharmaceutical Research.

[50]  E. R. Garrett Kinetics of antimicrobial action. , 1978, Scandinavian journal of infectious diseases. Supplementum.

[51]  D. Musher,et al.  Vancomycin penetration into biofilm covering infected prostheses and effect on bacteria. , 1994, The Journal of infectious diseases.

[52]  R. Vasilov,et al.  Prediction of the antimicrobial effects of trovafloxacin and ciprofloxacin on staphylococci using an in-vitro dynamic model. , 1999, The Journal of antimicrobial chemotherapy.

[53]  Jerome J. Schentag,et al.  Pharmacodynamic Evaluation of Factors Associated with the Development of Bacterial Resistance in Acutely Ill Patients during Therapy , 1998, Antimicrobial Agents and Chemotherapy.

[54]  N. Frimodt-Møller,et al.  Experimental infection with Streptococcus pneumoniae in mice: correlation of in vitro activity and pharmacokinetic parameters with in vivo effect for 14 cephalosporins. , 1986, The Journal of infectious diseases.

[55]  W. Craig Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporins. , 1995, Diagnostic microbiology and infectious disease.

[56]  J. Blaser,et al.  Efficacy of intermittent versus continuous administration of netilmicin in a two-compartment in vitro model , 1985, Antimicrobial Agents and Chemotherapy.

[57]  T. Vondracek,et al.  Beta-Lactam Antibiotics: Is Continuous Infusion The Preferred Method of Administration? , 1995, The Annals of pharmacotherapy.

[58]  A. Sánchez-Navarro,et al.  Basis of Anti-Infective Therapy , 1999, Clinical pharmacokinetics.

[59]  E. Bruck,et al.  National Committee for Clinical Laboratory Standards. , 1980, Pediatrics.

[60]  O. Cars,et al.  Pharmacodynamic effects of sub-MICs of benzylpenicillin against Streptococcus pyogenes in a newly developed in vitro kinetic model , 1996, Antimicrobial agents and chemotherapy.

[61]  R. Moore,et al.  Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration. , 1987, The Journal of infectious diseases.

[62]  C. Stratton,et al.  Correlation of serum bactericidal activity with antimicrobial agent level and minimal bactericidal concentration. , 1982, The Journal of infectious diseases.

[63]  B. Ledergerber,et al.  Computer-controlled in-vitro simulation of multiple dosing regimens. , 1985, The Journal of antimicrobial chemotherapy.

[64]  S. Palmer,et al.  An evaluation of the bactericidal activity of ampicillin/sulbactam, piperacillin/tazobactam, imipenem or nafcillin alone and in combination with vancomycin against methicillin-resistant Staphylococcus aureus (MRSA) in time-kill curves with infected fibrin clots. , 1997, The Journal of antimicrobial chemotherapy.

[65]  G. Kaatz,et al.  Bactericidal activities of teicoplanin, vancomycin, and gentamicin alone and in combination against Staphylococcus aureus in an in vitro pharmacodynamic model of endocarditis , 1994, Antimicrobial Agents and Chemotherapy.

[66]  J. Blaser,et al.  In-vitro studies of antibiotic combinations with special emphasis on the evaluation of newly developed methods. , 1986, The Journal of antimicrobial chemotherapy.

[67]  W. Craig Antibiotic selection factors and description of a hospital-based outpatient antibiotic therapy program in the USA , 1995, European Journal of Clinical Microbiology and Infectious Diseases.

[68]  Jerome J. Schentag,et al.  Pharmacokinetic and pharmacodynamic activities of ciprofloxacin against strains of Streptococcus pneumoniae, Staphylococcus aureus, and Pseudomonas aeruginosa for which MICs are similar , 1994, Antimicrobial Agents and Chemotherapy.

[69]  W. Craig Choosing an antibiotic on the basis of pharmacodynamics. , 1998, Ear, nose, & throat journal.

[70]  S. Palmer,et al.  Bactericidal killing activities of cefepime, ceftazidime, cefotaxime, and ceftriaxone against Staphylococcus aureus and beta-lactamase-producing strains of Enterobacter aerogenes and Klebsiella pneumoniae in an in vitro infection model , 1995, Antimicrobial agents and chemotherapy.

[71]  Jerome J. Schentag Pharmacokinetic and pharmacodynamic surrogate markers: studies with fluoroquinolones in patients. , 1999, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[72]  J. Blaser,et al.  Comparative study with enoxacin and netilmicin in a pharmacodynamic model to determine importance of ratio of antibiotic peak concentration to MIC for bactericidal activity and emergence of resistance , 1987, Antimicrobial Agents and Chemotherapy.

[73]  T. Bergan,et al.  An in vitro model for monitoring bacterial responses to antibiotic agents under simulated in vivo conditions , 2005, Infection.

[74]  M. Hammerschlag,et al.  In Vitro Activities of Azithromycin and Ofloxacin againstChlamydia pneumoniae in a Continuous-Infection Model , 1999, Antimicrobial Agents and Chemotherapy.

[75]  S. Zinner,et al.  Prediction of the Effects of Inoculum Size on the Antimicrobial Action of Trovafloxacin and Ciprofloxacin againstStaphylococcus aureus and Escherichia coli in an In Vitro Dynamic Model , 1999, Antimicrobial Agents and Chemotherapy.

[76]  J. Mordenti,et al.  Effect of dose on pharmacokinetics and serum bactericidal activity of mezlocillin , 1987, Antimicrobial Agents and Chemotherapy.

[77]  T. Bergan,et al.  Effect of antibiotics eliminated by first order kinetics. , 1985, Journal of Antimicrobial Chemotherapy.

[78]  W. Craig,et al.  Comparative antibiotic dose-effect relations at several dosing intervals in murine pneumonitis and thigh-infection models. , 1989, The Journal of infectious diseases.

[79]  R. van Furth,et al.  Comparison of the antibacterial activity of azlocillin and ticarcillin in vitro and in irradiated neutropenic mice. , 1985, The Journal of antimicrobial chemotherapy.

[80]  W. Craig,et al.  Pharmacokinetics and pharmacodynamics of antibiotics in meningitis. , 1999, Infectious disease clinics of North America.

[81]  A. Firsov,et al.  Quantitative analysis of antimicrobial effect kinetics in an in vitro dynamic model , 1990, Antimicrobial Agents and Chemotherapy.

[82]  J. Turnidge The pharmacodynamics of beta-lactams. , 1998, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[83]  J. Blaser,et al.  Two compartment kinetic model with multiple artificial capillary units. , 1985, The Journal of antimicrobial chemotherapy.

[84]  C. Colino,et al.  A retrospective analysis of pharmacokinetic/pharmacodynamic indices as indicators of the clinical efficacy of ciprofloxacin. , 2000, The Journal of antimicrobial chemotherapy.

[85]  A. Firsov,et al.  Parameters of bacterial killing and regrowth kinetics and antimicrobial effect examined in terms of area under the concentration-time curve relationships: action of ciprofloxacin against Escherichia coli in an in vitro dynamic model , 1997, Antimicrobial agents and chemotherapy.

[86]  B. Guglielmo,et al.  Comparative pharmacokinetics and serum inhibitory activity of clindamycin in different dosing regimens , 1988, Antimicrobial Agents and Chemotherapy.

[87]  G. Eliopoulos,et al.  Continuous-infusion ampicillin therapy of enterococcal endocarditis in rats , 1987, Antimicrobial Agents and Chemotherapy.

[88]  P. Francioli,et al.  Successful prophylaxis of experimental streptococcal endocarditis with single doses of sublethal concentrations of penicillin. , 1985, The Journal of antimicrobial chemotherapy.

[89]  W J Jusko,et al.  Pharmacodynamics of chemotherapeutic effects: dose-time-response relationships for phase-nonspecific agents. , 1971, Journal of pharmaceutical sciences.

[90]  H Derendorf,et al.  Basic concepts of pharmacokinetic/pharmacodynamic (PK/PD) modelling. , 1997, International journal of clinical pharmacology and therapeutics.

[91]  J. Waitz Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically , 1990 .

[92]  E. H. White,et al.  An In Vitro Tissue Culture Bilayer Model To Examine Early Events in Mycobacterium tuberculosisInfection , 1999, Infection and Immunity.

[93]  T. Drake,et al.  Effects of sub-bactericidal concentrations of antibiotics in experimental models of endocarditis. , 1985, Journal of Antimicrobial Chemotherapy.

[94]  T. Bergan,et al.  Bacterial kill rates of amoxycillin and ampicillin at exponentially diminishing concentrations simulating in vivo conditions , 2005, Infection.

[95]  H. Eichler,et al.  Target site concentrations after continuous infusion and bolus injection of cefpirome to healthy volunteers , 2000, Clinical pharmacology and therapeutics.

[96]  W. Craig,et al.  Pharmacodynamics of amikacin in vitro and in mouse thigh and lung infections. , 1991, The Journal of antimicrobial chemotherapy.

[97]  Jerome J. Schentag,et al.  Mathematical Examination of Dual Individualization Principles (I): Relationships between AUC above MIC and Area under the Inhibitory Curve for Cefmenoxime, Ciprofloxacin, and Tobramycin , 1991, DICP : the annals of pharmacotherapy.

[98]  E. R. Garrett,et al.  Kinetics and mechanisms of drug action on microorganisms. XVII. Bactericidal effects of penicillin, kanamycin, and rifampin with and without organism pretreatment with bacteriostatic chloramphenicol, tetracycline, and novobiocin. , 1973, Journal of pharmaceutical sciences.

[99]  J. Blaser,et al.  Impact of netilmicin regimens on the activities of ceftazidime-netilmicin combinations against Pseudomonas aeruginosa in an in vitro pharmacokinetic model , 1985, Antimicrobial Agents and Chemotherapy.

[100]  M. Nishida,et al.  New in vitro kinetic model for evaluating bactericidal efficacy of antibiotics , 1980, Antimicrobial Agents and Chemotherapy.

[101]  Carl Peck,et al.  An Evaluation of the Integration of Pharmacokinetic and Pharmacodynamic Principles in Clinical Drug Development , 1997, Clinical pharmacokinetics.

[102]  H. Eagle,et al.  THE RATE OF BACTERICIDAL ACTION OF PENICILLIN IN VITRO AS A FUNCTION OF ITS CONCENTRATION, AND ITS PARADOXICALLY REDUCED ACTIVITY AT HIGH CONCENTRATIONS AGAINST CERTAIN ORGANISMS , 1948, The Journal of experimental medicine.

[103]  C. Nightingale Pharmacokinetics of the oral cephalosporins in adults. , 1980, The Journal of international medical research.

[104]  W. Craig,et al.  Pharmacokinetics and pharmacodynamics of antibiotics in otitis media. , 1996, The Pediatric infectious disease journal.

[105]  A. Sanfilippo,et al.  An experimental model for the study of the antibacterial activity of the sulfonamides. , 1968, Chemotherapia.

[106]  G. Drusano Infection in the intensive care unit: beta-lactamase-mediated resistance among Enterobacteriaceae and optimal antimicrobial dosing. , 1998, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[107]  M. Sachdeva,et al.  Binding Affinity for Penicillin-Binding Protein 2a Correlates with In Activity of β-Lactan Antibiotics against Methicillin-Resistant Staphylococcus aureus , 1990 .

[108]  C. Edmiston,et al.  Pharmacodynamics of antimicrobial therapy in surgery. , 1996, American journal of surgery.

[109]  F. O'grady,et al.  An in vitro model of the urinary bladder. , 1978, The Journal of antimicrobial chemotherapy.

[110]  John M. Blatt,et al.  Description of the Model , 1988 .

[111]  S. Zinner,et al.  Inter- and Intraquinolone Predictors of Antimicrobial Effect in an In Vitro Dynamic Model: New Insight into a Widely Used Concept , 1998, Antimicrobial Agents and Chemotherapy.

[112]  W. Craig,et al.  Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. , 1998, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[113]  Schentag Jj,et al.  Potential impact of quantitative susceptibility tests on the design of aminoglycoside dosing regimens. , 1987 .

[114]  J. Guggenbichler,et al.  Kill kinetics of bacteria under fluctuating concentrations of various antibiotics. I. Description of the model. , 1986, Chemotherapy.

[115]  W. Craig Antimicrobial resistance issues of the future. , 1996, Diagnostic microbiology and infectious disease.

[116]  H. Mattie,et al.  Influence of aminopenicillins on bacterial growth kinetics in vitro in comparison with the antibacterial effect in vivo , 2005, Infection.

[117]  V. Tamassia,et al.  New In Vitro Model to Study the Effect of Antibiotic Concentration and Rate of Elimination on Antibacterial Activity , 1978, Antimicrobial Agents and Chemotherapy.

[118]  S. Zinner,et al.  A New Approach to In Vitro Comparisons of Antibiotics in Dynamic Models: Equivalent Area under the Curve/MIC Breakpoints and Equiefficient Doses of Trovafloxacin and Ciprofloxacin against Bacteria of Similar Susceptibilities , 1998, Antimicrobial Agents and Chemotherapy.

[119]  X. Barbaut,et al.  Comparisons between Antimicrobial Pharmacodynamic Indices and Bacterial Killing as Described by Using the Zhi Model , 1998, Antimicrobial Agents and Chemotherapy.

[120]  A. Widmer,et al.  In vivo verification of in vitro model of antibiotic treatment of device-related infection , 1995, Antimicrobial agents and chemotherapy.